Last reviewed · How we verify
Subconjunctival Avastin
Subconjunctival Avastin is a VEGF inhibitor (monoclonal antibody) Small molecule drug developed by Vanak Eye Surgery Center. It is currently in Phase 3 development for Age-related macular degeneration (wet AMD), Diabetic macular edema, Retinal vein occlusion.
Avastin (bevacizumab) inhibits vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel formation and leakage in the eye.
Subconjunctival Avastin, also known as bevacizumab, is an antibody that inhibits vascular endothelial growth factor A, a protein involved in the formation of new blood vessels. It has been studied in clinical trials for various conditions, including Diabetic Macular Edema, Neovascular, Glaucoma, Bleb Vascularity, and Bleb Fibrosis.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Subconjunctival Avastin |
|---|---|
| Sponsor | Vanak Eye Surgery Center |
| Drug class | VEGF inhibitor (monoclonal antibody) |
| Target | VEGF (vascular endothelial growth factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Bevacizumab is a monoclonal antibody that binds to and neutralizes VEGF, a key driver of pathological neovascularization and vascular permeability. When administered subconjunctivally (under the conjunctiva), it locally suppresses VEGF signaling to reduce edema, hemorrhage, and abnormal vessel growth in retinal and choroidal diseases. This off-label use leverages the drug's anti-angiogenic properties to treat various ocular conditions without systemic exposure.
Approved indications
- Age-related macular degeneration (wet AMD)
- Diabetic macular edema
- Retinal vein occlusion
- Proliferative diabetic retinopathy
Common side effects
- Conjunctival injection/hyperemia
- Subconjunctival hemorrhage
- Eye pain or discomfort
- Anterior chamber inflammation
- Endophthalmitis (rare)
Key clinical trials
- Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma (EARLY_PHASE1)
- Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization (PHASE2, PHASE3)
- Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian Patients (PHASE4)
- Pain Control and Subconjunctival Hemorrhage Size After Intravitreal Injection (NA)
- The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery (PHASE3)
- Outpatient Performed Pterygium Surgery Study (PHASE4)
- A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival (PHASE1, PHASE2)
- Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Subconjunctival Avastin CI brief — competitive landscape report
- Subconjunctival Avastin updates RSS · CI watch RSS
- Vanak Eye Surgery Center portfolio CI
Frequently asked questions about Subconjunctival Avastin
What is Subconjunctival Avastin?
How does Subconjunctival Avastin work?
What is Subconjunctival Avastin used for?
Who makes Subconjunctival Avastin?
What drug class is Subconjunctival Avastin in?
What development phase is Subconjunctival Avastin in?
What are the side effects of Subconjunctival Avastin?
What does Subconjunctival Avastin target?
Related
- Drug class: All VEGF inhibitor (monoclonal antibody) drugs
- Target: All drugs targeting VEGF (vascular endothelial growth factor)
- Manufacturer: Vanak Eye Surgery Center — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Age-related macular degeneration (wet AMD)
- Indication: Drugs for Diabetic macular edema
- Indication: Drugs for Retinal vein occlusion
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing